Patent · US Active

2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial

US8114881B2 · kind B2 · utility

0Cited by

7References

6Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

Peter Hansen · Staffanstorp, SE
Marianne Ivarsson · Lund, SE
Karolina Lawitz · Malmö, SE
Hans Roland LONN · Lund, SE
Antonios Nikitidis · Lund, SE
Asim Ray · Lund, SE

Key dates

Filing date	May 7, 2007
Grant date	Feb 14, 2012
Priority date	—
Expiry date	Jul 26, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D403/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides compounds of formulawherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.